Standout Papers

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or ... 2019 2026 2021 2023 716
  1. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial (2019)
    Ken Kato, Byoung Chul Cho et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 58 standout
Sub-graph 1 of 23

Citing Papers

Tandem-controlled lysosomal assembly of nanofibres induces pyroptosis for cancer immunotherapy
2025 Standout
Digestive cancers: mechanisms, therapeutics and management
2025 Standout
1 intermediate paper

Works of Eva Holtved being referenced

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
2019 Standout

Author Peers

Author Last Decade Papers Cites
Eva Holtved 596 628 479 19 991
M Mäntylä 580 322 835 31 1.2k
Jerrold B. Teitcher 513 365 345 22 1.3k
Wan-Yee Lau 309 432 175 14 1.1k
Maria Chiara Tronconi 681 1022 361 42 1.4k
William Alago 370 540 462 26 1.3k
Lisa Zuraw 493 675 603 12 1.4k
Matthew D. Callister 266 776 315 20 1.0k
Michael Garofalo 524 613 513 26 1.1k
Juan A. Díaz-González 430 520 196 26 1.0k
Rosella Spadi 351 1056 477 27 1.4k

All Works

Loading papers...

Rankless by CCL
2026